Eli Lilly's weight-loss drug is no longer on the Food and Drug Administration's drug shortage list. Compounding pharmacies ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

Eli Lilly (NYSE: LLY) sells treatments for a wide variety of therapeutic areas, but one portfolio in particular has driven ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of the wildly popular drug.

Eighty states, cities, counties, school boards and unions have joined litigation in a New Jersey district court against the three major pharmacy middlemen.

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

The Alliance for Pharmacy Compounding (APC) wants clarity around the FDA’s decision to reconsider tirzepatide’s removal from ...

A study suggests that weight loss medications like Ozempic may help reduce the risk of overdose and alcohol intoxication in ...

Streeting announced a collaboration with the world's largest pharmaceutical company, Lilly, which will include a five-year ...

Eli Lilly has announced a strategic collaboration with UK government departments to address population health challenges, ...

Obesity directly affects kidney health and influences chronic kidney disease (CKD) risk and progression through contributing ...